KRAS P.G12D

Clinical trials for KRAS P.G12D explained in plain language.

Never miss a new study

Get alerted when new KRAS P.G12D trials appear

Sign up with your email to follow new studies for KRAS P.G12D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill targets Hard-to-Treat cancer mutation in early human test

Disease control Recruiting now

This early-stage trial is testing an experimental oral drug called D3S-003 in 42 people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Particip…

Matched conditions: KRAS P.G12D

Phase: PHASE1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control

Last updated Jun 24, 2026 19:38 UTC

KRAS P.G12D

Get alerted when new KRAS P.G12D trials appear

New pill targets Hard-to-Treat cancer mutation in early human test